Advice
Advice has been withdrawn from the website
fosaprepitant (Ivemend®) 115mg powder for solution for infusion for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy was reviewed by SMC in October 2008. However from 15 February,2011, fosaprepitant (Ivemend®) 115mg powder for solution for infusion ceased to be available in the UK and therefore the SMC advice has been removed from the website.
Medicine details
- Medicine name:
- fosaprepitant (Ivemend)
- SMC ID:
- 506/08
- Indication:
- Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy
- Pharmaceutical company
- MSD
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 13 October 2008